May 23, 2024

Growing Prevalence of Autoimmune Disorders Drives the Global Autoimmune Polyglandular Syndrome Type 1 Market

The condition is primarily caused due to mutations in the AIRE gene, resulting in inadequate regulation of central immune tolerance and resultant autoimmune attacks on multiple endocrine tissues. Common conditions associated with APS1 include chronic mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency, and gonadal failure. Treatment of APS1 and associated autoimmune disorders relies on lifelong hormonal replacement or supplementation therapies.

The Global Autoimmune Polyglandular Syndrome Type 1 Market Size is primarily driven by the growing prevalence of autoimmune disorders and genetic mutations resulting in impaired immune tolerance. According to estimates.

The global APS1 market was valued at US$ 257 million in 2024 and is expected to expand at a CAGR of 3.1% during the forecast period of 2024-2031.

Geographically, North America dominated the APS1 market in 2024 owing to the rising incidence of autoimmune conditions and early diagnosis in the region.

Key players operating in the global APS1 market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Abbott, and LEO Pharma A/S.

Key Takeaways

Key players: Key players operating in the global APS1 market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Abbott, and LEO Pharma A/S.

Growing demand: The growing prevalence of autoimmune disorders due to genetic mutations and environmental factors has increased the demand for management of APS1 and associated conditions. Lifelong replacement or supplementation therapies are required to treat endocrine deficiencies in these patients.

Global expansion: Leading players in the APS1 market are expanding their geographical footprint through strategic collaborations and licensing agreements, especially in emerging markets. In addition, increasing healthcare expenditure and awareness about rare diseases are also supporting the market growth in developing regions.

Market Key Trends

One of the key trends gaining traction in the global APS1 market is the increasing focus on developing gene therapies for the disease. Since APS1 is primarily caused due to mutations in the AIRE gene, companies are investing in R&D of gene-based treatments such as gene silencing, gene editing, and gene replacement to address the root cause of the condition rather than just the symptoms. For instance, KSQ Therapeutics is developing an mRNA gene therapy candidate KSQ-1001 for APS1. Successful development of disease-modifying gene therapies has the potential to fundamentally alter the treatment paradigm of APS1 in the coming years.

Porter’s Analysis
Threat of new entrants: Low as substantial capital investment, economies of scale, and government regulations pose a significant barrier to entry.
Bargaining power of buyers: Moderate as switching costs are relatively low for buyers. However, specialized treatment limits options.
Bargaining power of suppliers: Moderate as some key inputs and technologies have few substitute options. However, suppliers still depend on the industry.
Threat of new substitutes: Low as the Autoimmune Polyglandular Syndrome Type 1 treatment market has few product or therapeutic alternatives.
Competitive rivalry: High as the market is saturated and competitors compete primarily on pricing and service.

Geographical Regions
North America currently accounts for the largest share of the global Autoimmune Polyglandular Syndrome Type 1 market owing to established healthcare facilities and high awareness levels. Europe follows North America closely due to favourable reimbursement policies and government support for rare disease treatment.

The Asia Pacific region is expected to witness the fastest growth during the forecast period due to rising healthcare spending, increasing prevalence of autoimmune disorders, and growing medical tourism. Countries like China, India, Japan, and South Korea are generating significant demand and introducing new treatment alternatives to aid growth.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it